NNNN revenueFY2025$8.65M
- FY YoY
- +5.6%
NNNN revenue was $8.65M for fiscal 2025 (ended Dec 31, 2025), up 5.6% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
Anbio Biotechnology (NNNN) financials
For fiscal 2025 (ended Dec 31, 2025), Anbio Biotechnology reported $8.65M of revenue and $6.40M of net income.
- Revenue, FY2025
- $8.65M
- Revenue growth, YoY
- +5.6%
- Net income, FY2025
- $6.40M
- Net income growth, YoY
- +169.9%
- Net margin
- 74.1%
- EPS, diluted, FY2025
- $0.15
- EPS growth, YoY
- +162.5%
- Cash
- $7.77M
- P/E
- 91.68
- P/S
- 67.89
- Market cap
- $587.1M
FY2022FY2025
FY2022FY2025
NNNN revenue and earnings growth
NNNN net incomeFY2025$6.40M
- FY YoY
- +169.9%
NNNN net income was $6.40M for fiscal 2025 (ended Dec 31, 2025), up 169.9% from fiscal 2024. It rose in 2 of the last 3 fiscal years.
NNNN EPSFY2025$0.15
- FY YoY
- +162.5%
NNNN diluted EPS was $0.15 for fiscal 2025 (ended Dec 31, 2025), up 162.5% from fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $8.65M | $8.19M | $6.71M | $23.54M |
| Cost of revenue | $1.10M | $2.30M | $3.35M | $10.98M |
| Gross profit | $7.54M | $5.89M | $3.36M | $12.56M |
| Research and development | $201.3K | $454.2K | $134.7K | $200.0K |
| Selling, general and admin | $1.57M | $3.44M | $1.27M | $2.17M |
| Operating income | $5.77M | $2.00M | $1.96M | $10.20M |
| Interest expense | - | - | - | $8.0K |
| Pre-tax income | $6.40M | $2.37M | $2.25M | $10.01M |
| Income tax | $0 | $0 | $0 | - |
| Net income | $6.40M | $2.37M | $2.25M | $10.01M |
| EPS, basic | $0.15 | $0.06 | $0.10 | $100112.00 |
| EPS, diluted | $0.15 | $0.06 | $0.10 | $100112.00 |
| Diluted shares | 43.7M | 42.3M | 21.4M | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $7.77M | $11.76M | $9.69M | $7.10M |
| Short-term investments | $4.13M | $0 | - | - |
| Receivables | $3.66M | $1.06M | $1.88M | - |
| Current assets | $30.24M | $18.53M | $15.75M | - |
| Total assets | $30.24M | $18.92M | $15.81M | - |
| Current liabilities | $87.8K | $1.73M | $993.1K | - |
| Total liabilities | $87.8K | $1.73M | $993.1K | - |
| Shareholders' equity | $30.16M | $17.19M | $14.82M | $12.55M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$6.74M | $2.08M | $898.4K | $4.45M |
| Investing cash flow | -$4.20M | $337.1K | $1.73M | -$1.53M |
| Financing cash flow | $6.95M | -$344.6K | -$42.8K | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | 5.6% | 21.9% | -71.5% | - |
| Net income growth, YoY | 169.9% | 5.3% | -77.5% | - |
| EPS growth, YoY | 162.5% | - | - | - |
| Gross margin | 87.2% | 71.9% | 50.1% | 53.4% |
| Operating margin | 66.7% | 24.4% | 29.2% | 43.3% |
| Net margin | 74.1% | 29.0% | 33.6% | 42.5% |
| Return on equity | 21.2% | 13.8% | 15.2% | 79.8% |
| Return on assets | 21.2% | 12.5% | 14.3% | - |
| Current ratio | 344.31 | 10.71 | 15.86 | - |
Source: XBRL data Anbio Biotechnology files with the SEC, latest filing dated Apr 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NNNN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NNNN | $8.65M | +5.6% | $6.40M | 74.1% | $587.1M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $55.67B |
| ORKA | - | - | -$152.57M | - | $6.92B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.61B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.64B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.45B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.70B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $829.5M |
| ACHV | - | - | -$114.04M | - | $697.7M |
NNNN FAQ
8 questionsWhat is NNNN revenue?
Anbio Biotechnology (NNNN) reported $8.65M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 5.6% from the year before.Is NNNN profitable?
Yes. Anbio Biotechnology earned $6.40M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 74.1%.How much cash and debt does NNNN have?
Anbio Biotechnology reported $7.77M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is NNNN revenue growing?
Anbio Biotechnology's revenue changed +5.6% in fiscal 2025, to $8.65M.What is NNNN gross margin?
Anbio Biotechnology's gross profit was $7.54M on $8.65M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 87.2%.What is NNNN earnings per share?
Diluted earnings per share were $0.15 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NNNN last report financial results?
The latest statements here come from Anbio Biotechnology's 20-F filed on Apr 7, 2026, covering the period ended Dec 31, 2025.Where does this NNNN financial data come from?
Quantisnow builds these statements from the structured XBRL data Anbio Biotechnology files with the SEC. It is provided for information only and is not investment advice.